Celldex Therapeutics

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Celldex Therapeutics  was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.
Type
Public
HQ
Hampton, US
Employees
196 (est)+51%
Celldex Therapeutics is headquartered in Hampton, US

Key People at Celldex Therapeutics

Tibor Keler

Tibor Keler

Founder, SVP & CSO
Harry H. Penner

Harry H. Penner

Co - Founder
Thomas Davis

Thomas Davis

SVP & CMO
Ronald A. Pepin

Ronald A. Pepin

SVP & Chief Business Officer
Avery W. Catlin

Avery W. Catlin

SVP & CFO
Anthony S. Marucci

Anthony S. Marucci

Founder, President & CEO

Celldex Therapeutics Locations

Hampton, US
Needham, US
Fall River, US
Branford, US

Celldex Therapeutics Metrics

Celldex Therapeutics Summary

Market capitalization

$381 M

Closing share price

$3.95
Celldex Therapeutics's latest market capitalization is $381 M.

Celldex Therapeutics Market Value History

Celldex Therapeutics News

Celldex Therapeutics Company Life